Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

9.960 +0.155 (+1.58%)
Streaming Delayed Price Updated: 2:17 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 108,375
Open 9.930
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 9.805
Today's Range 9.930 - 9.990
52wk Range 9.150 - 15.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets

Performance

YTD
-15.81%
-15.81%
1 Month
+0.61%
+0.61%
3 Month
-8.96%
-8.96%
6 Month
-15.16%
-15.16%
1 Year
-33.69%
-33.69%

More News

Read More
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Via Benzinga
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
Via Investor's Business Daily
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
Via Benzinga
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
Via The Motley Fool
Why Is Seagen Stock Trading Higher Today?
Via Benzinga
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
Via Investor's Business Daily
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
Via Benzinga
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
Via Investor's Business Daily
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Via Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Via Talk Markets
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Why Shares of Annexon Are Plummeting Thursday
Via The Motley Fool
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
Via Benzinga
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
Via Benzinga
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
Via The Motley Fool
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
Via Benzinga
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Via Investor's Business Daily
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Via Benzinga
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
Via Benzinga
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
Via Benzinga
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.